Other languages Algernon Pharmaceuticals Inc.

Equities

AGN

CA01559R4008

Market Closed - Canadian Securities Exchange Other stock markets 14:50:41 2024-05-10 EDT			5-day change	1st Jan Change
0.125 ^CAD	+13.64%		+13.64%	+92.31%

04-30	Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	CI
04-10	Algernon Pharmaceuticals Inc. announced that it has received CAD 0.017 million in funding	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-29
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug Dmt Stroke Research Program as Its Lead Asset	04-01
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company	03-27
Algernon Pharmaceuticals Inc. acquired 20% stake in Seyltx, Inc.	03-26
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	01-25
Algernon Pharmaceuticals Inc. Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis	01-24
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	12-29
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD	11-30
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-07-28
Algernon Pharmaceuticals Engages Maxim Group to Provide Financial Advisory and Investment Banking Services, and to Assist in Identifying and Evaluating Potential M&A and Strategic Opportunities	23-06-27
Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD	23-05-31
Algernon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-05-01
Algernon Neuroscience Appoints Dr. David Brody to Advisory Board	23-03-21
Algernon Pharmaceuticals Inc. Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase	23-02-16
Algernon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	23-01-29
Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board	23-01-11
Algernon Pharmaceuticals Inc. Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil	23-01-09
Algernon Pharmaceuticals Inc. Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program	23-01-03
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis	22-12-05
Algernon Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	22-11-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Algernon Pharmaceuticals Inc.

Equities

AGN

CA01559R4008

Other languages

Filters